(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

7 Straits View #12-00, Marina One East Tower

Singapore

EXHIBITS.

Description

Signature

Title

Date

/s/ Paul B. Bolno, M.D., MBA

/s/ Kyle Moran

/s/ Christian Henry

/s/ Mark H. N. Corrigan, M.D.

/s/ Peter Kolchinsky, Ph.D.

/s/ Adrian Rawcliffe

/s/ Ken Takanashi

/s/ Aik Na Tan

/s/ Gregory L. Verdine, Ph.D.

/s/ Heidi L. Wagner, J.D.

WongPartnership LLP 12

Marina Boulevard Level 28

Marina Bay Financial Centre Tower 3

Singapore 018982

T +65 6416 8000

wongpartnership.com

ASEAN | CHINA | MIDDLE EAST

Date: 9 November 2023

FROM

LJV/JNJM/20160703

The Board of Directors

Wave Life Sciences Ltd.

c/o 733 Concord Avenue

Cambridge, MA 02138

United States of America

f:+65 6532 5711

Not for service of court documents

Not for urgent correspondence

d:+65 6416 6465

e:jenvern.loh@wongpartnership.com

Introduction

We have acted as legal advisers to the Company, a company incorporated under the laws of the Republic of Singapore, as to Singapore law in connection with the filing by the Company with the United States Securities and Exchange Commission (the “Commission”) of a registration statement on Form S-8 (the “Registration Statement”) under the Securities Act of 1933, as amended (the “Securities Act”), in respect of 6,500,000 additional ordinary shares of the Company (the “2021 Plan Shares”) reserved for issuance under the Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended (the “2021 Plan”).

We do not express nor imply any opinion with respect to the effect of any law other than the laws of the Republic of Singapore as of the date of this opinion, and have made no investigation of, and do not express or imply views of, any other laws which may be relevant to the documents submitted or made available to us or opinions given by us, nor do we express or imply any opinion on matters relating to tax. This opinion is to be governed by and construed in accordance with the laws of the Republic of Singapore as applied by the courts of the Republic of Singapore as of the date of this opinion. All references to the laws of the Republic of Singapore or a specific law of the Republic of Singapore in this opinion are references to the laws of the Republic of Singapore as applied by the courts of the Republic of Singapore as of the date of this opinion. We are not obliged to update this opinion to reflect, or notify any addressee of this opinion or any other person of, any legal or legislative developments, or other changes to law or fact, arising after the date of this opinion. We have taken instructions solely from the Company.

In respect of the 2021 Plan and the 2021 Plan Shares, we have assumed due compliance with all matters concerning the laws of the United States of America and all other relevant jurisdictions (other than in the Republic of Singapore in respect of the matters set out in paragraph 7 of this opinion).

Documents

In rendering the opinions set out below, we have examined:

WongPartnership LLP (UEN: T08LL0003B) is a limited liability law partnership

registered in Singapore under the Limited Liability Partnerships Act 2005.

an electronic copy (in Adobe Acrobat form) of the certificate of incorporation of the Company dated 24 July 2012 issued by the Accounting and Corporate Regulatory Authority of the Republic of Singapore (“ACRA”);

an electronic copy (in Adobe Acrobat form) of the certificate confirming incorporation upon conversion of the Company dated 6 November 2015 issued by ACRA confirming the Company’s conversion to a public company;

an electronic copy (in Adobe Acrobat form) of the constitution of the Company, as amended on 9 November 2015 (the “Constitutive Documents”);

electronic copies (in Adobe Acrobat form) of the minutes of a meeting of the Board of Directors of the Company (the “Board”) held on 15 June 2021, resolutions in writing of the Board dated 25 June 2022, the minutes of a meeting of the Board held on 7 June 2023, and the minutes of meetings of the compensation committee of the Board held on 6 June 2022, 22 June 2022 and 7 June 2023 (the “Board Resolutions”);

electronic copies (in Adobe Acrobat form) of the minutes dated 18 August 2021 of the annual general meeting of the Company held on 10 August 2021, the minutes dated 9 August 2022 of the annual general meeting of the Company held on 9 August 2022 and the minutes dated 1 August 2023 of the annual general meeting of the Company held on 1 August 2023 (the “Shareholders’ Resolutions” and together with the Board Resolutions, the “Resolutions”);

an electronic copy (in Adobe Acrobat form) of the 2021 Plan appended as Exhibit 10.1 to the Company’s current report on Form 8-K pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, filed by the Company with the Commission on 7 August 2023;

an electronic copy (in Adobe Acrobat form) of the Registration Statement; and

such other documents as we may have considered necessary or desirable to examine in order that we may render this opinion.

This opinion is being rendered to you in connection with the filing of the Registration Statement. Except as expressly provided in paragraph 7 of this opinion, we express no opinion whatsoever with respect to any document described in paragraph 4 herein.

Assumptions

We have assumed (without enquiry and with your consent):

all signatures (including without limitation marks or text purporting to be signatures) (whether electronic or otherwise) on all documents submitted or made available to us (a) are genuine and authentic, (b) have not been altered or tampered with in any way, and (c) are in compliance with the constitutive documents of the parties (if a company) and the Electronic Transactions Act 2010 of the Republic of Singapore, and that each such signature is that of a person duly authorised to affix the same and execute the relevant documents in the manner it was executed, and, where a document was signed by electronic signature or purported to be signed in that manner, was affixed at the direction of (or provided by) such person, the authenticity of all documents submitted or made available to us as originals, and the completeness and the conformity to original documents of all copies submitted or made available to us;

that each document submitted or made available to us for examination is true, complete and up-to-date, has not been revoked, repudiated, terminated, amended or superseded, and all representations, warranties, assumptions and factual statements contained therein are true and correct;

that the Resolutions were:

duly passed at properly convened meetings of duly appointed directors or the shareholders of the Company, or a duly constituted committee of the Board, or as the case may be, duly passed in the form of circulating resolutions in writing, in accordance with the provisions of the Constitutive Documents; and

duly passed in accordance with the provisions of the Companies Act 1967 of the Republic of Singapore (the “Companies Act”);

that the copy of the 2021 Plan appended as Exhibit 10.1 to the Company’s current report on Form 8-K pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, filed by the Company with the Commission on 7 August 2023, is true, complete and up-to-date, and has not been revoked, rescinded, superseded or amended and is in full force and effect, and that no other resolution or other action has been passed or taken which could affect the validity of the 2021 Plan;

that the approvals conferred by the copies of the Resolutions submitted to us have not been revoked, rescinded, superseded or amended and are in full force and effect, and that no other resolution or other action has been passed or taken which could affect the validity of any or all of the Resolutions;

that the directors of the Company:

have been duly appointed in accordance with the provisions of the Companies Act and the Constitutive Documents;

have acted and will act in good faith and in the best interests of the Company in approving the preparation, execution and filing of the Registration Statement with the Commission, the entry into the transactions contemplated in the 2021 Plan (including, but without limitation, the grant of individual awards and issuance of the 2021 Plan Shares), and without intention to defraud any of the creditors of the Company; and

have each disclosed and will disclose any interest which the director may have in the 2021 Plan and the 2021 Plan Shares in accordance with the provisions of the Companies Act and the Constitutive Documents and except as disclosed, none of the directors of the Company has or will have any interest in such transactions except to the extent permitted by the Companies Act and the Constitutive Documents;

that all relevant documents have been provided to us by the officers of the Company for inspection for the purposes of this opinion;

that the individual grants, purchases and issuances under the 2021 Plan are duly authorised by all necessary corporate actions of the Company;

that the individual grants, purchases and issuances are made under the 2021 Plan and the 2021 Plan Shares are duly issued in accordance with the requirements of applicable law (other than the laws of the Republic of Singapore in respect of the opinions in paragraph 7), the rules of the 2021 Plan and the individual grants, and in compliance with Section 77 of the Companies Act;

that, at the time of the individual grants, purchases and issuances of the 2021 Plan Shares, the Company has obtained a mandate from shareholders of the Company to issue ordinary shares of the Company pursuant to Section 161 of the Companies Act (the “Share Issue Mandate”) and such Share Issue Mandate has not expired in accordance with its terms or been previously revoked or varied by the Company in general meeting;

that the 2021 Plan Shares to be issued under the terms of the 2021 Plan and the individual grants will be duly registered in the names of the persons who had been granted and issued the 2021 Plan Shares, or in the name of the Depository Trust Company or its nominee, as the case may be, and the certificates for the 2021 Plan Shares will be duly issued and delivered;

that no law (including, without limitation, any public policy) of any jurisdiction outside the Republic of Singapore is relevant to or affects the opinions expressed or conclusions stated in this opinion;

that there shall be the absence of fraud, bad faith, undue influence, coercion, duress, mistake or misrepresentation on the part of the Company and its respective officers, employees, agents and advisers;

that all acts, conditions or things required to be fulfilled, performed or effected in connection with the allotment and issue of the 2021 Plan Shares under the laws of any jurisdiction (other than by the Company under the laws of the Republic of Singapore in relation to the matters set out in paragraph 7 of this opinion) will be duly fulfilled, performed and complied with;

that there are no provisions of the laws of any jurisdiction (other than the laws of the Republic of Singapore in relation to the matters set out in paragraph 7 of this opinion) which will be contravened by the allotment and issue of the 2021 Plan Shares and that, insofar as any obligation expressed to be incurred or performed under the 2021 Plan and to the extent relevant, in connection with the allotment and issue of the 2021 Plan Shares, falls to be performed in or is otherwise subject to the laws of any jurisdiction (other than the Republic of Singapore in relation to the matters set out in paragraph 7 of this opinion), its performance will not be illegal by virtue of the laws of that jurisdiction;

that all applicable consents, approvals, authorisations, licences, exemptions or orders required from any applicable governmental or other regulatory authorities and all other requirements for allotment and issue of the 2021 Plan Shares (other than those required by the Company under the laws of the Republic of Singapore in relation to the matters set out in paragraph 7 of this opinion) have been (and have not been withdrawn) or will be duly obtained or fulfilled, and are (and will remain) in full force and effect, and that any conditions to which they are subject have been (or will be) satisfied;

that there are no agreements, documents, arrangements or transactions to which the Company is a party to that may in any way prohibit or restrict the allotment and issue of the 2021 Plan Shares;

that the Constitutive Documents will not be amended in a manner that would have the effect of rendering any of our opinions in paragraph 7 inaccurate;

that no foreign law is relevant to or affects the conclusions stated in this opinion, and none of the opinions expressed herein will be affected by the laws (including, without limitation, the public policy) of any jurisdiction outside the Republic of Singapore, and insofar as the laws of any jurisdiction outside the Republic of Singapore may be relevant, such laws have been or will be complied with; and

that none of the 2021 Plan, the individual grants, the 2021 Plan Shares or any of the transactions contemplated under the 2021 Plan and the awards granted under the 2021 Plan constitutes or will constitute a sham.

Opinion

Based on the foregoing, and subject to the assumptions, limitations and qualifications set forth herein and having regard to such legal considerations as we have deemed relevant and subject to any matters not disclosed to us, we are of the opinion that, the 2021 Plan Shares will, when issued and delivered by the Company in accordance with the Constitutive Documents and the terms of the 2021 Plan, and pursuant to the laws of the Republic of Singapore against payment of such amounts required in accordance with the rules of the 2021 Plan and the individual grants, be validly issued, fully paid and non-assessable.

Qualifications

This opinion is subject to the following qualifications:

for the purposes of this opinion, we have assumed that the term “non-assessable” (a term which has no recognised meaning under the laws of the Republic of Singapore) in relation to the 2021 Plan Shares to be issued means that holders of such shares, having fully paid up all amounts due on such shares, or such shares having been credited as fully paid up, as the case may be, are under no further personal liability to make payments to the Company or its creditors or contribute to the assets or liabilities of the Company in their capacities purely as holders of such shares;

we are not responsible for, and have not investigated or verified, the accuracy or completeness of the facts and information, including any statements of foreign law, or the reasonableness of any assumptions, statements of opinion or intention, contained in the documents referred to in paragraph 4 of this opinion. We do not express any opinion as to any matters of fact generally, including statements of foreign law, or the reasonableness of any assumptions or statements of opinion or intention, contained in the documents described in paragraph 4. In addition, we are not responsible for investigating or verifying whether any material fact has been omitted from such documents;

we express no opinion as to the validity, binding effect or enforceability of any provision in the 2021 Plan, the individual grants or, where applicable, the 2021 Plan Shares by reference to a law other than that of the Republic of Singapore, or as to the availability in the Republic of Singapore of remedies which are available in other jurisdictions;

with respect to matters of fact material to this opinion, we have relied on the statements of the responsible officers of the Company;

we have only examined a copy of the Registration Statement and not the information or documents incorporated by reference to the Registration Statement; and

this opinion is strictly limited to matters stated in this opinion and is not to be construed as extending (by implication or otherwise) to the documents listed in paragraph 4 of this opinion, or to any other matter or document in connection with, referred to, contemplated by or incorporated by reference, in such documents.

We hereby consent to the use of our opinion as herein set forth as an exhibit to the Registration Statement. In giving this consent, we do not hereby admit and shall not be deemed to admit that we come within the category of persons whose consent is required under Sections 7 and 11 of the Securities Act or to the rules and regulations of the Commission thereunder.

This opinion is only for the benefit of the person to whom it is addressed, subject to the condition that such person accepts and acknowledges that this opinion may not be appropriate or sufficient for such person’s purposes, and is strictly limited to the matters stated in this opinion and is not to be read as extending by implication to any other matter in connection with the 2021 Plan, or otherwise, including, but without limitation, any other document (including the Registration Statement). Further, except for the filing of this opinion with the Commission as an exhibit to the Registration Statement, this opinion is not to be circulated to, or relied upon by, any other person (other than persons entitled to rely on it pursuant to applicable provisions of federal securities law in the United States of America, if any) or quoted or referred to in any public document or filed with any governmental body or agency without our prior written consent.

Yours faithfully

/s/ WongPartnership LLP

WONGPARTNERSHIP LLP

Security
Class

Title

Proposed
Maximum

Offering
Price Per
Unit(3)

Maximum
Aggregate

Offering

Price

Fee

Rate

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers an indeterminate number of additional ordinary shares, no par value (“Ordinary Shares”), of Wave Life Sciences Ltd. (the “Registrant”), which may be subject to grant or otherwise issuable after the operation of any anti-dilution and other provisions of the Registrant’s 2021 Equity Incentive Plan, as amended (the “2021 Plan”).

Represents an increase of 6,500,000 Ordinary Shares of the Registrant reserved for issuance under the 2021 Plan approved by the Registrant’s shareholders at the 2023 Annual General Meeting of Shareholders.

Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate offering price for shares reserved for future grant or issuance under the 2021 Plan are based on the average of the high and the low price of the Registrant’s Ordinary Shares as reported on The Nasdaq Global Market as of a date (November 3, 2023) within five business days prior to filing this Registration Statement.